Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders
Samira Luisa Apostolos-Pereira,Lis Campos Ferreira,Mateus Boaventura,Nise Alessandra de Carvalho Sousa,Gabriela Joca Martins,José Arthur d'Almeida,Milena Pitombeira,Lucas Silvestre Mendes,Thiago Fukuda,Hideraldo Luíz Souza Cabeça,Luciano Chaves Rocha,Bianca Santos de Oliveira,Carla Renata Vieira Stella,Enedina Maria Lobato de Oliveira,Leizian de Souza Amorim,Andréa Ferrari de Castro,Antonio Pereira Gomes Neto,Guilherme Diogo Silva,Lucas Bueno,Maria de Morais Machado,Rafael Castello Dias-Carneiro,Ronaldo Maciel Dias,Alvaro Porto Moreira,Ana Piccolo,Anderson Kuntz Grzesiuk,Andre Muniz,Caio Diniz Disserol,Claudia Ferreira Vasconcelos,Damacio Kaimen-Maciel,Denise Sisterolli Diniz,Elizabeth Comini-Frota,Fernando Coronetti Rocha,Gutemberg Augusto Cruz Dos Santos,Yara Dadalti Fragoso,Guilherme Sciascia do Olival,Heloisa Helena Ruocco,Heloise Helena Siqueira,Henry Koity Sato,José Alexandre Figueiredo Jr,Leandro Cortoni Calia,Mario Emilio Teixeira Dourado Jr,Letícia Scolari,Herval Ribeiro Soares Neto,Luiz Melges,Marcus Vinicius Magno Gonçalves,Maria Lucia Vellutini Pimentel,Marlise de Castro Ribeiro,Omar Gurrola Arambula,Paulo Diniz da Gama,Renata Leite Menon,Rodrigo Barbosa Thomaz,Rogério de Rizo Morales,Silvana Sobreira,Suzana Nunes Machado,Taysa Gonsalves Jubé Ribeiro,Valéria Coelho Santa Rita Pereira,Vanessa Maia Costa,Adaucto Wanderley da Nóbrega Junior,Soniza Vieira Alves-Leon,Marilia Mamprim de Morais Perin,Eduardo Donadi,Tarso Adoni,Sidney Gomes,Maria Brito Ferreira,Dagoberto Callegaro,Maria Fernanda Mendes,Doralina Brum,Felipe von Glehn,Neuroimmunology Brazilian Study Group
DOI: https://doi.org/10.1212/NXI.0000000000001060
2021-08-26
Abstract:Background and objectives: To describe the clinical features and disease outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorder (NMOSD). Methods: The Neuroimmunology Brazilian Study Group has set up the report of severe acute respiratory syndrome (SARS-CoV2) cases in patients with NMOSD (pwNMOSD) using a designed web-based case report form. All neuroimmunology outpatient centers and individual neurologists were invited to register their patients across the country. Data collected between March 19 and July 25, 2020, were uploaded at the REDONE.br platform. Inclusion criteria were as follows: (1) NMOSD diagnosis according to the 2015 International Panel Criteria and (2) confirmed SARS-CoV2 infection (reverse transcription-polymerase chain reaction or serology) or clinical suspicion of COVID-19, diagnosed according to Center for Disease Control / Council of State and Territorial Epidemiologists (CDC/CSTE) case definition. Demographic and NMOSD-related clinical data, comorbidities, disease-modifying therapy (DMT), COVID-19 clinical features, and severity were described. Results: Among the 2,061 pwNMOSD followed up by Brazilian neurologists involved on the registry of COVID-19 in pwNMOSD at the REDONE.br platform, 34 patients (29 women) aged 37 years (range 8-77), with disease onset at 31 years (range 4-69) and disease duration of 6 years (range 0.2-20.5), developed COVID-19 (18 confirmed and 16 probable cases). Most patients exhibited mild disease, being treated at home (77%); 4 patients required admission at intensive care units (severe cases); and 1 patient died. Five of 34 (15%) presented neurologic manifestations (relapse or pseudoexacerbation) during or after SARS-CoV2 infection. Discussion: Most NMOSD patients with COVID-19 presented mild disease forms. However, pwNMOSD had much higher odds of hospitalization and intensive care unit admission comparing with the general Brazilian population. The frequency of death was not clearly different. NMOSD disability, DMT type, and comorbidities were not associated with COVID-19 outcome. SARS-CoV2 infection was demonstrated as a risk factor for NMOSD relapses. Collaborative studies using shared NMOSD data are needed to suitably define factors related to COVID-19 severity and neurologic manifestations.